(Pyrimidin-5-yl)boronic acid → (2-Methyl-5-pyrimidin-5-yl-[1,7]naphthyridin-8-yl)-(2-methyl-thiazol-4-yl)-amine
Reaction equation
Cl[C:2]1[N:3]=[CH:4][C:5](I)=[C:6]2[C:11]=1[N:10]=[C:9]([CH3:12])[CH:8]=[CH:7]2.[N:14]1[CH:19]=[C:18](B(O)O)[CH:17]=[N:16][CH:15]=1.[NH2:23][C:24]1[N:25]=[C:26]([CH3:29])[S:27][CH:28]=1>>[CH3:12][C:9]1[CH:8]=[CH:7][C:6]2[C:11](=[C:2]([NH:23][C:24]3[N:25]=[C:26]([CH3:29])[S:27][CH:28]=3)[N:3]=[CH:4][C:5]=2[C:18]2[CH:19]=[N:14][CH:15]=[N:16][CH:17]=2)[N:10]=1Participants
4
Procedure
The title compound, MS: m/e=335.2 (M+H+), was prepared in accordance with the general method of example 15 step 1 and step 3 from 8-chloro-5-iodo-2-methyl-[1,7]naphthyridine (Example I), 5-pyrimidineboronic acid and 4-amino-2-methylthiazole (Example F).
Sources & evidence
- ORD record
- ord-ff9ffbf26f7e49d2b69a8e069fa50e22
- Source dataset
- uspto-grants-2009_03
- Patent number
- US07511055B2
Reaction notes
Loading…